Pharma and Patient Advocates Offer Competing Visions for Achieving Vaccine Equity During Pandemics

“Big Pharma’s unwillingness to acknowledge that the existing IP regime did not just enable innovation — it also produced artificially restricted supplies, price profiteering, and grossly inequitable distribution first of vaccines and tests and now of Covid medicines as well,” Professor Brook Baker ’76, senior policy analyst for Health GAP, tells STAT.